Winning Grants

Sean Ekins is founder and CEO of Collaborations Pharmaceuticals, Inc. which is focused on using machine learning approaches for rare and neglected disease drug discovery. Sean graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He was a postdoctoral fellow at Lilly Research Laboratories, before working as a senior scientist at Pfizer and then Eli Lilly. He went on to join several startup companies at increasingly senior levels. Since 2005 he has been awarded numerous grants and since 2016 alone has won over 20 from NIH and DOD (STTR/SBIR grants, R21, UH2 and R01) totaling over $16.7M, as well as performing as a consultant on others. He has a passion for advancing new technologies for drug discovery and is a prolific collaborator. He has authored or co-authored >345 peer reviewed papers, book chapters, edited 5 books on different aspects of drug discovery research and use (and misuse) of AI. Coverage of such researchhas also appeared in the Economist, Financial Times and Washington Post.

Sean Ekins 是 Collaborations Pharmaceuticals, Inc. 的創辦人兼執行長，該公司專注於利用機器學習方法進行罕見病和被忽視疾病的藥物發現。Sean 畢業於阿伯丁大學，獲得臨床藥理學的碩士、博士學位及科學博士學位。他曾在 Lilly Research Laboratories 擔任博士後研究員，之後在 Pfizer 和 Eli Lilly 擔任高級科學家。他隨後加入幾家初創公司，並逐步晉升至更高的職位。自 2005 年以來，他獲得了多項資助，自 2016 年以來更是獲得了來自 NIH 和 DOD 的 20 多項資助（包括 STTR/SBIR 資助、R21、UH2 和 R01），總額超過 1670 萬美元，並擔任其他項目的顧問。他熱衷於推進藥物發現的新技術，並且是一位多產的合作者。他已發表或共同發表超過 345 篇經過同行評審的論文、書籍章節，編輯了 5 本有關藥物發現研究不同方面的書籍，以及 AI 的使用（和誤用）。這些研究的報導也曾出現在《經濟學人》、《金融時報》和《華盛頓郵報》。